Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Specimen Handling 65Magnetic Resonance Spectroscopy 44Cyclophosphamide 31Carboplatin 31Gemcitabine 30Biopsy 28Cisplatin 25Bevacizumab 25Radiotherapy 24pembrolizumab 23Paclitaxel 23Standard of Care 22Oxaliplatin 22Nivolumab 21Drug Therapy 21Capecitabine 21venetoclax 20fludarabine 20Interviews as Topic 18Injections 17Blood Specimen Collection 16toripalimab 15Radiosurgery 15Dexamethasone 15Azacitidine 15tislelizumab 14Irinotecan 14cemiplimab 13anlotinib 13Docetaxel 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × famitinib × 90 days × Clear all
NCT07517653 2026-04-08

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡